Efficacy and safety of subcutaneous mosunetuzumab in combination with lenalidomide and as a monotherapy in Japanese patients with relapsed/refractory follicular lymphoma [0.03%]
Mosunetuzumab皮下注射联合来那度胺或单药治疗复发/难治性滤泡淋巴瘤的日本患者中疗效和安全性研究
Shinichi Makita,Koji Izutsu,Yuko Mishima et al.
Shinichi Makita et al.
Background: JO40295 (jRCT2080223801) evaluated the efficacy and safety of subcutaneous (SC) mosunetuzumab, in combination with lenalidomide and as monotherapy, in Japanese patients with relapsed/refractory (R/R) follicula...
Current development and challenges of NK cell-based immunotherapy for gastrointestinal cancers [0.03%]
基于NK细胞的免疫治疗在胃肠肿瘤中目前的进展和挑战
Situo Zheng,Yosuke Morodomi,Yoshikazu Yonemitsu
Situo Zheng
Despite multimodal treatment options, most gastrointestinal (GI) cancers remain associated with high mortality rates and poor responsiveness to immunotherapy. The remarkable success of immune cell-based therapies in hematologic malignancies...
Lack of molecular mimicry between HPV vaccine L1 antigen and human proteins by a computational analysis [0.03%]
计算分析人乳头瘤病毒疫苗L1抗原与人类蛋白质之间缺乏分子模拟表位证据
Kazuhiro Nishioka,Kentaro Sekiyama,Reona Shiro et al.
Kazuhiro Nishioka et al.
Background: Although human papillomavirus (HPV) vaccines effectively prevent cervical cancer, the HPV vaccination rates in Japan remain low because of concerns about alleged neurological adverse events. Darja Kanduc propo...
Correction to: Policy recommendations for promoting nuclear medicine therapy in Japan 2025, from the Working Group for promoting nuclear medicine therapy of the Japan Society of Clinical Oncology [0.03%]
日本临床肿瘤学会推动核医学治疗工作组2025年促进日本核医学治疗的政策建议的更正通知
Kotaro Suzuki,Hideaki Miyake,Anri Inaki et al.
Kotaro Suzuki et al.
Published Erratum
International journal of clinical oncology. 2026 Jan 8. DOI:10.1007/s10147-025-02925-9 2026
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; imlunestrant for breast cancer, tafasitamab for follicular lymphoma, atezolizumab for thymic carcinoma, retifanlimab for anal canal squamous cell carcinoma, and tagraxofusp for blastic plasmacytoid dendritic cell neoplasm [0.03%]
日本PMDA关于抗癌药物审批和修订使用注意事项的监管更新；Imlunestrant用于乳腺癌，Tafasitamab用于滤泡性淋巴瘤，Atezolizumab用于胸腺癌，Retifanlimab用于肛门鳞状细胞癌，Tagraxofusp用于原始浆样树突细胞肿瘤
Noriomi Matsumura
Noriomi Matsumura
Real-world effectiveness and safety of lisocabtagene maraleucel for relapsed/refractory large B cell lymphoma in Japan [0.03%]
利沙单抗注射液治疗复发/难治性大B细胞淋巴瘤的现实世界有效性及安全性（日本）
Tetsuro Ochi,Shinichi Makita,Anna Hiratsuka et al.
Tetsuro Ochi et al.
Background: Lisocabtagene maraleucel (liso-cel), an anti-CD19 CAR T cell therapy, has demonstrated efficacy in relapsed/refractory (R/R) large B cell lymphoma (LBCL). However, real-world data from commercial settings outs...
Real-world safety and efficacy of immune checkpoint inhibitors in Japanese patients with persistent, recurrent, or metastatic cervical cancer: a multicenter prospective and retrospective study [0.03%]
日本持续性、复发性或转移性宫颈癌患者免疫检查点抑制剂的真实世界疗效和安全性：多中心前瞻性及回顾性研究
Kazuhisa Kitami,Shiho Kuji,Natsuko Kamiya et al.
Kazuhisa Kitami et al.
Objective: To evaluate the real-world safety and efficacy of immune checkpoint inhibitors (ICIs) in Japanese patients with persistent, recurrent, or metastatic cervical cancer. ...
Sequential changes in conditional survival of patients following surgical resection of colorectal cancer and indicators for follow-up beyond 5 years [0.03%]
结直肠癌手术切除患者条件生存的连续变化及5年以上随访指标的研究
Ryotaro Goto,Hideo Miyake,Hidemasa Nagai et al.
Ryotaro Goto et al.
Background: The evolving prognosis of colorectal cancer (CRC) over extended periods following surgery has not been comprehensively characterized. This study aimed to delineate long-term patterns in conditional survival (C...
Longitudinal assessment of health-related quality of life, sleep quality, and gustation in patients with advanced urothelial carcinoma receiving late-line enfortumab vedotin monotherapy [0.03%]
恩萨鲁肽单药治疗晚期尿路上皮癌患者纵向评估与健康相关生命质量、睡眠质量和味觉有关的状况
Makito Miyake,Nobutaka Nishimura,Yuki Oda et al.
Makito Miyake et al.
Background: To describe real-world data on health-related quality of life (HRQoL) in patients with locally advanced or metastatic urothelial carcinoma receiving late-line enfortumab vedotin (EV) monotherapy. ...
Cancer epidemiology in rare and hereditary colorectal diseases 2) anal canal cancer (cancer statistics) [0.03%]
罕见和遗传性结直肠病的流行病学 2)肛管癌（癌症统计）
Kazutaka Yamada,Yasumitsu Saiki,Shota Takano et al.
Kazutaka Yamada et al.
Background: Anal canal carcinoma (ACC) is reported to be a rare cancer worldwide. In Japan, while the incidence rate is similarly low compared to Western countries, its histological distribution differs. This paper aimed ...